CONTEXT: Haemophilus influenzae type b (Hib) conjugate vaccine is not perceived as a public health priority in Africa because data on Hib disease burden and vaccine effectiveness are scarce. Hib immunization was introduced in Kenyan infants in 2001. OBJECTIVE: To define invasive Hib disease incidence and Hib vaccine program effectiveness in Kenya. DESIGN, SETTING, AND PATIENTS: Culture-based surveillance for invasive Hib disease at Kilifi District Hospital from 2000 through 2005 was linked to demographic surveillance of 38,000 children younger than 5 years in Kilifi District, Kenya. Human immunodeficiency virus (HIV) infection and Hib vaccination status were determined for children with Hib disease admitted 2002-2005. INTERVENTIONS: Introduction of conjugate Hib vaccine within the routine childhood immunization program at ages 6, 10, and 14 weeks beginning November 2001. MAIN OUTCOME MEASURES: Incidence of culture-proven Hib invasive disease before and after vaccine introduction and vaccine program effectiveness. RESULTS: Prior to vaccine introduction, the median age of children with Hib was 8 months; case fatality was 23%. Among children younger than 5 years, the annual incidence of invasive Hib disease 1 year before and 1 and 3 years after vaccine introduction was 66, 47, and 7.6 per 100,000, respectively. For children younger than 2 years, incidence was 119, 82, and 16 per 100,000, respectively. In 2004-2005, vaccine effectiveness was 88% (95% confidence interval, 73%-96%) among children younger than 5 years and 87% (95% confidence interval, 66%-96%) among children younger than 2 years. Of 53 children with Hib admitted during 2002-2005, 29 (55%) were age-ineligible to have received vaccine, 12 (23%) had not been vaccinated despite being eligible, and 12 (23%) had received 2 or more doses of vaccine (2 were HIV positive). CONCLUSIONS: In Kenya, introduction of Hib vaccine into the routine childhood immunization program reduced Hib disease incidence among children younger than 5 years to 12% of its baseline level. This impact was not observed until the third year after vaccine introduction.
CONTEXT: Haemophilus influenzae type b (Hib) conjugate vaccine is not perceived as a public health priority in Africa because data on Hib disease burden and vaccine effectiveness are scarce. Hib immunization was introduced in Kenyan infants in 2001. OBJECTIVE: To define invasive Hib disease incidence and Hib vaccine program effectiveness in Kenya. DESIGN, SETTING, AND PATIENTS: Culture-based surveillance for invasive Hib disease at Kilifi District Hospital from 2000 through 2005 was linked to demographic surveillance of 38,000 children younger than 5 years in Kilifi District, Kenya. Human immunodeficiency virus (HIV) infection and Hib vaccination status were determined for children with Hib disease admitted 2002-2005. INTERVENTIONS: Introduction of conjugate Hib vaccine within the routine childhood immunization program at ages 6, 10, and 14 weeks beginning November 2001. MAIN OUTCOME MEASURES: Incidence of culture-proven Hib invasive disease before and after vaccine introduction and vaccine program effectiveness. RESULTS: Prior to vaccine introduction, the median age of children with Hib was 8 months; case fatality was 23%. Among children younger than 5 years, the annual incidence of invasive Hib disease 1 year before and 1 and 3 years after vaccine introduction was 66, 47, and 7.6 per 100,000, respectively. For children younger than 2 years, incidence was 119, 82, and 16 per 100,000, respectively. In 2004-2005, vaccine effectiveness was 88% (95% confidence interval, 73%-96%) among children younger than 5 years and 87% (95% confidence interval, 66%-96%) among children younger than 2 years. Of 53 children with Hib admitted during 2002-2005, 29 (55%) were age-ineligible to have received vaccine, 12 (23%) had not been vaccinated despite being eligible, and 12 (23%) had received 2 or more doses of vaccine (2 were HIV positive). CONCLUSIONS: In Kenya, introduction of Hib vaccine into the routine childhood immunization program reduced Hib disease incidence among children younger than 5 years to 12% of its baseline level. This impact was not observed until the third year after vaccine introduction.
Authors: K Mulholland; S Hilton; R Adegbola; S Usen; A Oparaugo; C Omosigho; M Weber; A Palmer; G Schneider; K Jobe; G Lahai; S Jaffar; O Secka; K Lin; C Ethevenaux; B Greenwood Journal: Lancet Date: 1997-04-26 Impact factor: 79.321
Authors: R A Adegbola; S O Usen; M Weber; N Lloyd-Evans; K Jobe; K Mulholland; K P McAdam; B M Greenwood; P J Milligan Journal: Lancet Date: 1999-09-25 Impact factor: 79.321
Authors: Richard A Adegbola; Ousman Secka; George Lahai; Nellie Lloyd-Evans; Alpha Njie; Stanley Usen; Claire Oluwalana; Stephen Obaro; Martin Weber; Tumani Corrah; Kim Mulholland; Keith McAdam; Brian Greenwood; Paul J M Milligan Journal: Lancet Date: 2005 Jul 9-15 Impact factor: 79.321
Authors: Samba O Sow; Souleymane Diallo; James D Campbell; Milagritos D Tapia; Tatiana Keita; Mamadou Marouf Keita; Patrick Murray; Karen L Kotloff; Myron M Levine Journal: Pediatr Infect Dis J Date: 2005-06 Impact factor: 2.129
Authors: James A Berkley; Brett S Lowe; Isaiah Mwangi; Thomas Williams; Evasius Bauni; Saleem Mwarumba; Caroline Ngetsa; Mary P E Slack; Sally Njenga; C Anthony Hart; Kathryn Maitland; Mike English; Kevin Marsh; J Anthony G Scott Journal: N Engl J Med Date: 2005-01-06 Impact factor: 91.245
Authors: Shabir A Madhi; Locadiah Kuwanda; Leena Saarinen; Clare Cutland; Rosalia Mothupi; Helena Käyhty; Keith P Klugman Journal: Vaccine Date: 2005-08-01 Impact factor: 3.641
Authors: G Campagne; A Garba; A Schuchat; D Boulanger; B D Plikaytis; M Ousseini; J P Chippaux Journal: Am J Trop Med Hyg Date: 1998-11 Impact factor: 2.345
Authors: Charlotte F McAuley; Clare Webb; Julie Makani; Alexander Macharia; Sophie Uyoga; Daniel H Opi; Carolyne Ndila; Antony Ngatia; John Anthony G Scott; Kevin Marsh; Thomas N Williams Journal: Blood Date: 2010-06-08 Impact factor: 22.113
Authors: James A Berkley; Patrick Munywoki; Mwanajuma Ngama; Sidi Kazungu; John Abwao; Anne Bett; Ria Lassauniére; Tina Kresfelder; Patricia A Cane; Marietjie Venter; J Anthony G Scott; D James Nokes Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: Thomas N Williams; Sophie Uyoga; Alex Macharia; Carolyne Ndila; Charlotte F McAuley; Daniel H Opi; Salim Mwarumba; Julie Makani; Albert Komba; Moses N Ndiritu; Shahnaaz K Sharif; Kevin Marsh; James A Berkley; J Anthony G Scott Journal: Lancet Date: 2009-09-09 Impact factor: 79.321